GhayasC.IssaMD

PubMed

• 1 citations
  Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.
  Wei-Ying Jen, Jennifer Marvin-Peek, Hagop M Kantarjian, Yesid Alvarado, Gautam Borthakur
  Cancer. 2025-01-01
• 5 citations
  Menin Inhibition With Revumenib for-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
  Ghayas C Issa, Ibrahim Aldoss, Michael J Thirman, John DiPersio, Martha Arellano
  Journal of Clinical Oncology. 2025-01-01
• 3 citations
  Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL.
  Hagop Kantarjian, Nicholas J Short, Fadi G Haddad, Nitin Jain, Xuelin Huang
  Journal of Clinical Oncology. 2024-12-20

Abstracts/Posters

• Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Com...
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute ...
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic...
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Sequencing of Circulating Cell-Free DNA in Patients with AML Detects Clinically Significant Mutations Not Detected in Bone Marrow: The Role for Complementary Periphera...
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remis...
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Phase I Clinical Trial of CK0801 (cord blood regulatory T cells) in Patients with Bone Marrow Failure Syndrome (BMF) Including Aplastic Anemia, Myelodysplasia and Myel...
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphob...
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute...
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Identification of Gene Expression Signatures in Leukemia Stem Cells and Minimal Residual Disease Following Treatment of Adverse Risk Acute Myeloid Leukemia 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leu... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older P... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018